# BIOCRYST PHARMACEUTICALS INC (BCRX) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from BIOCRYST PHARMACEUTICALS INC's 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/BCRX/mda/fy2025/): filed 2026-02-26; accession 0001628280-26-012240 (https://www.sec.gov/Archives/edgar/data/882796/000162828026012240/bcrx-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/BCRX/mda/fy2024/): filed 2025-02-25; accession 0001628280-25-007715 (https://www.sec.gov/Archives/edgar/data/882796/000162828025007715/bcrx-20241231.htm)
- [FY 2023 MD&A](/company/BCRX/mda/fy2023/): filed 2024-02-27; accession 0001628280-24-007205 (https://www.sec.gov/Archives/edgar/data/882796/000162828024007205/bcrx-20231231.htm)
- [FY 2022 MD&A](/company/BCRX/mda/fy2022/): filed 2023-02-27; accession 0001628280-23-005259 (https://www.sec.gov/Archives/edgar/data/882796/000162828023005259/bcrx-20221231.htm)
- [FY 2021 MD&A](/company/BCRX/mda/fy2021/): filed 2022-02-28; accession 0001171843-22-001460 (https://www.sec.gov/Archives/edgar/data/882796/000117184322001460/bcrx20211231_10k.htm)

Back to /company/BCRX/